This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
BioNTech (BNTX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On BioNTech's (BNTX) second-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, developed in partnership with Pfizer.
PFENegative Net Change SRPTNegative Net Change BNTXNegative Net Change
biotechs
Stock Futures Indicate Higher Opening on Strong Q2 Earnings
by Zacks Equity Research
Stock futures rise in pre-market trade on impressive second-quarter earnings results.
ATVINegative Net Change BPPositive Net Change COPPositive Net Change AMGNNegative Net Change PRUNegative Net Change MTCHPositive Net Change UAAPositive Net Change
biotechs consumer-discretionary insurance oil-energy retail
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
SNYPositive Net Change DVAXPositive Net Change AMGNNegative Net Change AMRNNegative Net Change
biotechs
Novavax (NVAX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming second-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
SNYPositive Net Change NVAXPositive Net Change SRPTNegative Net Change
biotechs
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
REGNPositive Net Change SNYPositive Net Change IRWDNegative Net Change ZTSNegative Net Change
biotechs earnings
Drug/Biotech Stock Q2 Earnings on Aug 3: LLY, AMGN & More
by Kinjel Shah
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
ALNYNegative Net Change LLYNegative Net Change AMGNNegative Net Change INCYPositive Net Change
biotechs pharmaceuticals
Editas (EDIT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) second-quarter earnings call, investor focus will likely be on the company's progress with the development of EDIT-101, its lead pipeline candidate.
ILMNNegative Net Change SRPTNegative Net Change ABBVPositive Net Change EDITNegative Net Change
biotechs
Is a Beat Likely for Moderna (MRNA) This Earnings Season?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Moderna's (MRNA) authorized coronavirus vaccine, on the second-quarter earrings call.
AZNNegative Net Change DVAXPositive Net Change PFENegative Net Change MRNAPositive Net Change
biotechs
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on updates on pipeline candidates, especially NTLA-2001, when Intellia (NTLA) reports second-quarter earnings.
REGNPositive Net Change MRNAPositive Net Change PRTANegative Net Change NTLANegative Net Change
biotechs
Seagen (SGEN) Q2 Earnings Beat Estimates, Revenues Surge Y/Y
by Zacks Equity Research
Seagen (SGEN) reports narrower-than-expected loss for the second quarter of 2021 while revenues beat estimates.
GSKPositive Net Change RHHBYNegative Net Change SGENPositive Net Change GMABPositive Net Change
biotechs earnings
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
NVONegative Net Change GILDPositive Net Change ICPTPositive Net Change VKTXNegative Net Change
biotechs earnings pharmaceuticals
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.
GSKPositive Net Change MRKPositive Net Change GILDPositive Net Change RGENNegative Net Change
biotechs pharmaceuticals
Blueprint Medicines (BPMC) Misses on Q2 Earnings & Revenues
by Zacks Equity Research
Blueprint Medicines (BPMC) misses estimates for revenues and earnings in the second quarter of 2021. Nevertheless, the company provides encouraging pipeline updates.
RHHBYNegative Net Change RGENNegative Net Change VNDAPositive Net Change
biotechs
What's in Store for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla Repatha and other and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
REGNPositive Net Change LLYNegative Net Change AMGNNegative Net Change MRNAPositive Net Change
biotechs
Vertex (VRTX) Q2 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Vertex's (VRTX) earnings and sales beat estimates in the second quarter of 2021. The company raises revenue guidance for the year.
VRTXNegative Net Change RGENNegative Net Change TECHNegative Net Change CRSPNegative Net Change
biotechs
Ligand (LGND) Q2 Earnings & Sales Beat, 2021 Guidance Cut
by Zacks Equity Research
Ligand (LGND) reports encouraging second-quarter 2021 numbers by beating estimates on both counts.
MRKPositive Net Change AMGNNegative Net Change GILDPositive Net Change LGNDNegative Net Change
biotechs
CRISPR Therapeutics (CRSP) Q2 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
CRISPR Therapeutics' (CRSP) earnings and revenues beat estimates in the second quarter of 2021. Pipeline development in focus.
VRTXNegative Net Change RGENNegative Net Change TECHNegative Net Change CRSPNegative Net Change
biotechs
Emergent (EBS) Misses on Q2 Earnings, to Restart Bayview Unit
by Zacks Equity Research
Emergent's (EBS) second-quarter 2021 earnings miss estimates. Revenues also fail to meet expectations. Stock down.
AZNNegative Net Change JNJPositive Net Change CDXSNegative Net Change EBSNegative Net Change
biotechs earnings
Bear of the Day: NeoGenomics (NEO)
by Kevin Cook
Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff
NEONegative Net Change EXASPositive Net Change NVTAPositive Net Change NTRANegative Net Change GHNegative Net Change
biotechs cancer genetics genomics medical
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
REGNPositive Net Change NVSPositive Net Change IRWDNegative Net Change JNJPositive Net Change ZTSNegative Net Change BHCNegative Net Change
biotechs earnings pharmaceuticals
BioMarin (BMRN) Beats on Q2 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin (BMRN) beats on both earnings and revenues in the second quarter of 2021.
SNYPositive Net Change BMRNPositive Net Change RGENNegative Net Change TECHNegative Net Change
biotechs earnings
Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.
DVAXPositive Net Change CRVSNegative Net Change BNGONo Net Change
biotechs
Alkermes (ALKS) Beats on Q2 Earnings & Sales, Ups '21 View
by Zacks Equity Research
Following a positive recovery from COVID-impacts, Alkermes (ALKS) beat both earnings and sales estimates in second-quarter 2021. The company also raised its guidance for 2021.
MRKPositive Net Change ALKSNegative Net Change ARVNNegative Net Change BCYCNegative Net Change
biotechs
Stock Market News for Jul 29, 2021
by Zacks Equity Research
U.S. stock markets closed mixed on Wednesday following the Fed's decision to keep interest rate near zero.
BAPositive Net Change PFENegative Net Change ODFLNegative Net Change BNTXNegative Net Change
aerospace biotechs pharmaceuticals transportation
Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.
BMYNegative Net Change PFENegative Net Change RGENNegative Net Change AGENNegative Net Change
biotechs earnings